BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12056035)

  • 1. [Treatment of metastatic germ cell tumors with etoposide and cisplatin as first line chemotherapy].
    Shintaku I; Numahata K; Suzuki K; Ohyama C; Sato M; Saito S; Hoshi S; Orikasa S
    Nihon Hinyokika Gakkai Zasshi; 2002 May; 93(4):519-24. PubMed ID: 12056035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
    J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
    Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
    Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.
    Tjulandin SA; Garin AM; Mescheryakov AA; Perevodchikova NI; Gorbunova VA; Sokolov AV; Ljubimova NV; Mironova GT; Molchanov GV; Ozols RF
    Ann Oncol; 1993 Sep; 4(8):663-7. PubMed ID: 8240996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
    Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
    J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to high-dose cisplatin and etoposide in advanced germ cell tumors in children: results of the Brazilian Germ Cell Tumor Study.
    Lopes LF; de Camargo B; Dondonis M; de Araujo RA; Morinaka E
    Med Pediatr Oncol; 1995 Nov; 25(5):396-9. PubMed ID: 7674997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
    Kondagunta GV; Bacik J; Bajorin D; Dobrzynski D; Sheinfeld J; Motzer RJ; Bosl GJ
    J Clin Oncol; 2005 Dec; 23(36):9290-4. PubMed ID: 16361627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
    Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-drug therapy in patients with metastatic germ cell tumors.
    Bajorin DF; Geller NL; Weisen SF; Bosl GJ
    Cancer; 1991 Jan; 67(1):28-32. PubMed ID: 1845937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
    Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
    Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
    Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
    J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late relapse of germ cell tumors after cisplatin-based chemotherapy.
    Gerl A; Clemm C; Schmeller N; Hentrich M; Lamerz R; Wilmanns W
    Ann Oncol; 1997 Jan; 8(1):41-7. PubMed ID: 9093706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
    Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C
    Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
    Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
    J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.